Page 103 - Read Online

Offin et al. J Cancer Metastasis Treat 2023;9:21 Journal of Cancer
DOI: 10.20517/2394-4722.2022.140
Metastasis and Treatment

Review Open Access

The past, present, and future of targeted therapeutic
approaches in patients with diffuse pleural

mesotheliomas

1
1,#
2,#
Michael Offin , Bailey Fitzgerald , Marjorie G. Zauderer , Deborah Doroshow 2
1
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College,
New York, NY 10065, USA.
2
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
10029, USA.
#
Authors contributed equally.
Correspondence to: Dr. Michael Offin, Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer
Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10065, USA. E-mail: offinm@mskcc.org
How to cite this article: Offin M, Fitzgerald B, Zauderer MG, Doroshow D. The past, present, and future of targeted therapeutic
approaches in patients with diffuse pleural mesotheliomas. J Cancer Metastasis Treat 2023;9:21.
https://dx.doi.org/10.20517/2394-4722.2022.140

Received: 14 Dec 2022 First Decision: 6 Apr 2023 Revised: 13 Apr 2023 Accepted: 10 May 2023 Published: 31 May 2023

Academic Editors: Pravin Potdar, Palanisamy Nallasamy, Ciro Isidoro, Robert Arthur Kratzke Copy Editor: Fangling Lan
Production Editor: Fangling Lan

Abstract
Despite our growing understanding of the genomic landscape of diffuse pleural mesotheliomas (DPM), there has
been limited success in targeted therapeutic strategies for the disease. This review summarizes attempts to
develop targeted therapies in DPM, focusing on the following targets being clinically explored in recent and
ongoing clinical trials: vascular endothelial growth factor, mesothelin, BRCA1-associated protein 1, Wilms tumor 1
protein, NF2/YAP/TAZ, CDKN2, methylthioadenosine phosphorylase, v-domain Ig suppressor T-cell activation,
and argininosuccinate synthetase 1. Although preclinical data for these targets are promising, few have
efficaciously translated to benefit our patients. Future efforts should seek to expand the availability of preclinical
models that faithfully recapitulate DPM biology, develop clinically relevant biomarkers, and refine patient selection
criteria for clinical trials.

Keywords: Mesothelioma, targeted therapy, biomarkers, genomics

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.jcmtjournal.com